Cellular Therapy to Repair, Regenerate and Restore
Developing therapeutics derived from cells within our own body whose function is to repair and regenerate tissue at the site of damage, inflammation and disease.
We are a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. Through patient-focused, regenerative medicine, our research and therapies are aimed at improving healthspan.
The number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging; The function and ability to do activities of daily living.
“Longevity is increasing. There is heightened focus on living longer, but that comes at a cost. A key goal within the medical community is to enhance the quality of life during the aging process – to improve healthspan.
At Longeveron, we hypothesize that stem cells might reduce the difficulties associated with aging and offer improved quality of life for patients with life-threatening conditions.”
Dr. Joshua Hare
Co-founder, Chief Science Officer and Chairman
HLHS is a congenital birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing. As a consequence, babies born with this condition have severely diminished systemic blood flow, which requires children to undergo a complex, three stage heart reconstruction surgery process over the course of the first 5 years of their lives. We are testing the ability for cell therapy to improve cardiac function in these children.
HLHS is a congenital birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing. As a consequence, babies born with this condition have severely diminished systemic blood flow, which requires children to undergo a complex, three stage heart reconstruction surgery process over the course of the first 5 years of their lives. We are testing the ability for cell therapy to improve cardiac function in these children.
Alzheimer’s disease, which affects nearly 7 million Americans, is a neurodegenerative disorder that leads to progressive memory loss and death. There are few drugs available for treating Alzheimer’s disease, and none that affect the long-term progression of the disease. Longeveron has partnered with the Alzheimer’s Association to advance clinical research using a cell therapy approach to treating this devastating disease.
Alzheimer’s disease, which affects over 5 million Americans, is a neurodegenerative disorder that leads to progressive memory loss and death. There are few drugs available for treating Alzheimer’s disease, and none that affect the long-term progression of the disease. Longeveron has partnered with the Alzheimer’s Association to advance clinical research using a cell therapy approach to treating this devastating disease.
Can we extend the period of time that we live in relatively good health, free of chronic disease, dependence and disability, a period known as “healthspan”? Individuals with Aging Frailty are at higher risk for adverse health outcomes such as falls, fractures, loss of independence, susceptibility to infection, institutionalization, hospitalization and death. At Longeveron, we are leading the efforts to develop a regenerative medicine approach for intervention and treatment of Aging Frailty.
Can we extend the period of time that we live in relatively good health, free of chronic disease, dependence and disability, a period known as “healthspan”? Individuals with Aging Frailty are at higher risk for adverse health outcomes such as falls, fractures, loss of independence, susceptibility to infection, institutionalization, hospitalization and death. At Longeveron, we are leading the efforts to develop a regenerative medicine approach for intervention and treatment of Aging Frailty.
Conference Call and Webcast Details:
Conference Call Number:
1.877.407.0789
Conference ID:
13751432
Date: Feb 28, 2025
Time: 4:05 PM ET
Call meTM Feature:>
Webcast>
Our CEO Wa’el Hashad participated in an interview with Benzinga All Access to discuss recent updates and progress across our clinical development program, including Top Line Results for CLEAR MIND Alzheimer’s disease Phase 2a Trial.
Watch a replay of the interview here
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming Dawson James Small Cap Growth Conference taking place in Jupiter, Florida from October 11-12, 2022.
Read More >>
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for rare pediatric disease, aging-related conditions, and unmet medical needs, today announced the appointment of seasoned global pharmaceutical leader Wa’el Hashad as Chief Executive Officer. Mr. Hashad will assume the role of Chief Executive Officer effective March 1, 2023. Following Mr. Hashad joining Longeveron, current Interim Chief Executive Officer Chris Min, M.D., Ph.D., will continue in his role as Chief Medical Officer.
Read More >>
Executive brings more than 30 years of global biopharmaceutical operations and program management experience
MIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations.
Read More >>
Click here to replay our KOL event, which was held on August 16, 2023, featuring Sunjay Kaushal, MD, PhD and Ram Kumar Subramanyan, MD, PhD, discussing the potential for Medicinal Signaling Cells (MSCs), such as those making up Longeveron’s Lomecel-B™ injection, to improve the outcome for Hypoplastic Left Heart Syndrome (HLHS) patients.
Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad,
Elected to Board at Annual Meeting of Stockholders
Read More >>
Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-B TM compared to 20% mortality rate observed from historical control data
Read More >>
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the first patient has been treated with Lomecel-B™ in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll 45 patients and its primary objective is to evaluate safety.
Read More >>
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the publication of the full results from the Company’s ELPIS I trial of Lomecel-BTM for hypoplastic left heart syndrome (HLHS) in the European Heart Journal Open. In the uncontrolled open-label Phase 1b study entitled “Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: The ELPIS phase I trial,” patients (n=10) underwent the Glenn Procedure (an open heart surgery) at approximately 4-5 months old, and received intracardiac injections of Lomecel-BTM.
Read More >>
New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting approximately 1,000 babies per year
MIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the U.S.
Read More >>
Click here to replay our KOL event, which was held on August 16, 2023, featuring Sunjay Kaushal, MD, PhD and Ram Kumar Subramanyan, MD, PhD, discussing the potential for Medicinal Signaling Cells (MSCs), such as those making up Longeveron’s Lomecel-B™ injection, to improve the outcome for Hypoplastic Left Heart Syndrome (HLHS) patients.
Click Here to Watch the Replay
